Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: Past, present, and future

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Shire, Norah J ^a   Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; DIDANOSINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; VIRUS RNA; ZIDOVUDINE;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER FAILURE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SUPERINFECTION; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 20844463260     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429498     Document Type: Review

References (36)

1. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 2003; 33:356-64.
2. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38:575-7.
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
4. Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6:203-8.
5. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
6. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 1584-9.
7. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362-4.
8. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
9. Douglas DD, Rakela J, Lin HJ, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993; 38:601-7.
10. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-89.
11. Cristiano K, Di Bisceglie AM, Hoofnagle JH, Feinstone SM. Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets. Arch Virol Suppl 1992; 4:172-8.
12. Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115:700-4.
13. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
15. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
16. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
17. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
18. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, consensus statement. European Association for the Study of the Liver. J Hepatol 1999; 30:956-61.
19. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585-91.
20. Sanchez JF, Pascua J, Sanchez F, Crespo L, Briones A, Martin C. Treatment of chronic hepatitis C virus infection with interferon in patients infected with the human immunodeficiency virus [in Spanish]. An Med Interna 1994; 11:575-9.
21. Boldorini R, Vigano P, Monga G, et al. Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon. J Clin Pathol 1997; 50:735-40.
22. Causse X, Payen JL, Izopet J, Babany G, Girardin MF. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group. J Hepatol 2000; 32:1003-10.
23. Landau A, Batisse D, Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14:839-44.
24. Nasti G, Di Gennaro G, Tavio M, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS 2001; 15:1783-7.
25. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-32.
26. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-8.
27. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
28. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
29. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs. standard intereron alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
30. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
31. Sherman KE, Horn P, Rouster S, Peters M, Koziel M, Chung R. HCV RNA kinetic response to PEG-interferon and ribavirin in HCV co-infected patients [oral abstract 122). In: Program and abstracts of the 9th Conference on Retrovirus and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:93.
32. Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188:1498-507.
33. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
34. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004;38:e79-80.
35. Artsaenko O, Tessmann K, Sack M, Haussinger D, Heintges T. Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies. J Gen Virol 2003; 84:2323-32.
36. Godofsky E, Afdhal NH, Rustgi VK, et al. A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283, a novel antiviral treatment for hepatitis C [abstract 407]. In: Program and abstracts of Digestive Disease Week (New Orleans). Gastroenterology 2004; 126(Suppl 2):A-681.